INTRODUCTION
Human pancreatic cancer is a devastating disease characterized by a very poor prognosis. Today, it is the fourth leading cause of cancer-related death in the European Community and in North America. 1, 2 Little is known about the causes of this disease which is difficult to diagnose in its early stages, and patients with inoperable pancreatic cancer have a dismal prognosis with a mean life expectancy of 3-6 months. 2, 3 For a long time, 5-fluorouracil was the most widely used chemotherapeutic agent in metastatic pancreatic cancer. However, it had only a modest effect and was associated with high systemic toxicity. 4, 5 At present gemcitabine, a pyrimidine analogue of deoxycytidine with a wide range of antitumor activity against solid tumors, has become the standard of care for patients with locally advanced and metastatic pancreatic cancer. [6] [7] [8] In randomized trials, gemcitabine was the first and only chemotherapeutic agent that has been shown to have any meaningful impact on either survival or disease-related symptoms in pancreatic adenocarcinoma with few systemic side effects. 9 Although this drug improves the quality of life in many patients, it prolongs survival of pancreatic cancer patients by only a few months. 10 The reasons for the resistance of pancreatic cancer to therapy are not clearly understood, but the multidrug resistant mechanisms and the lack of response to apoptotic stimuli are widely recognized in cancer chemotherapy. 11 Thus, in spite of some progress having been achieved in the treatment of pancreatic cancer, the majority of the patients still succumb to cancer, and it is clear that better treatment strategies are urgently needed. The future of pancreatic cancer therapy may lie in the new fields of targeted and molecular therapies. Besides improvement of the conventional chemotherapy, cancer gene therapy is a particularly promising approach, and includes the use of suicide gene/prodrug systems, inhibition of oncogene expression, blocking of tumor angiogenesis, antitumor immuno-modulation, and tumor-specific apoptosis induction.
The failure of chemotherapy can be attributed, at the cellular level, to an acquired resistance to apoptosis. Therefore devising mechanisms to restore the apoptotic process in tumor cells may help in the design of effective therapeutic strategies against resistant cancers. 12, 13 In the recent past, a wide variety of apoptosis-inducing molecules have been identified. Two major apoptotic pathways originating from separate subcellular compartments have been identified as (i) the death receptor-mediated "extrinsic apoptotic pathway" and (ii) the mitochondrion-mediated "intrinsic apoptotic pathway". 14, 15 While each pathway is initially mediated by different mechanisms, they share a common final phase of apoptosis, consisting of activation of the executioner caspases and dismantling of the substrates that are critical for cell survival. Several studies separately using the proapoptotic genes, Bax and TNF-related apoptosis-inducing ligand (TRAIL), showed that their overexpression leads to apoptosis in a wide variety of tumor cell lines; these genes appear to be promising candidates for cancer therapeutics. 15, 16 It is therefore rational to study the proapoptotic activity of TRAIL and Bax together in cancer cells.
On the basis of these data, and taking into account the generally favorable toxicity profile of gemcitabine in patients, we hypothesize that simultaneous overexpression of Bax and TRAILinduced apoptosis pathways would elicit a stronger antitumor effect and chemosenzitisation of pancreatic cancer.
In order to prevent any apoptotic side-effect in normal cells, selective and targeted gene expression can be achieved through transcriptional regulation using tissue-or cell-specific promoter elements. Human telomerase reverse transcriptase (hTERT), the catalytic subunit of the telomerase, is virtually undetectable in most normal tissues 17 and is transcriptionally upregulated in more than 80% of tumor cells, including pancreatic cancer. 18, 19 By reducing cytotoxicity in normal cells, the use of specific promoters provides a clear advantage over the strong constitutive promoters such as the human cytomegalovirus (CMV) and the phosphoglycerate kinase (PGK) promoters.
In the present study, we propose a single bicistronic adenoviral vector containing an internal ribosome entry segment (IRES) to express Bax-ires-GFP or TRAIL-ires-GFP under the control of hTERT promoter, using an inducible Gal4/GV16 fusion protein by modifying the Tet-Off system. The efficacy of these recombinant adenoviruses, named Ad-igBax and Ad-igTRAIL, was evaluated alone and in combination with gemcitabine, both in vitro and in vivo in pancreatic carcinoma models.
The results of the present study demonstrate that targeted overexpression of apoptosis-inducing Bax and TRAIL genes in combination with gemcitabine might provide an effective approach to pancreatic cancer therapy.
RESULTS

Construction of the recombinant adenoviruses Ad-igBax and Ad-igTRAIL
In order to reduce the adenoviral dose and to solve the problem of production and amplification of adenovirus-expressing toxic or apoptotic genes, we opted for a tetracycline-inducible system for Bax and TRAIL expression targeting, using the hTERT promoter. In addition, in order to facilitate the evaluation of the adenovirus function, Bax and TRAIL genes were co-expressed with green fluorescent protein (GFP), using an IRES element. We thus designed bicistronic tetracycline inducible adenoviruses named Ad-igBax and Ad-igTRAIL. On the basis of the Tet-Off system, the hTERT promoter drives the expression of a transactivator fusion protein TetR/VP16 (Figure 1a) . In the absence of tetracycline, tTA binds to tetracycline-responsive element (TRE) and induces the expression of GFP, Bax, and TRAIL. The functionality of these adenovirus constructions was evaluated, and it was indicated that low concentrations of tetracycline were able to inhibit Bax expression. Indeed, at 0.1 µg/ml of tetracycline treatment, Bax expression was drastically inhibited; using 1 µg/ml of tetracycline the level was close to the endogenous Bax protein. Moreover, the tumor cells infected with Ad-igBax, without any treatment, showed a high Bax protein expression, comparable to that induced by the binary system combining Ad/PGK-GV16 and Ad/GT-Bax (Figure 1b) .
Apoptosis-inducible gene expression is restricted to telomerase-positive tumor cells
In order to assess the transcriptional activity of the hTERT promoter, Panc-1, Capan-1, and fibroblast cells were infected with Ad-igTRAIL or Ad-igBax [multiplicity of infection (MOI) 50] in the presence or absence of hTERT-small interfering RNA (hTERT-siRNA) (100 nmol/l). Reverse transcriptase-polymerase chain reaction (RT-PCR) assay demonstrated that infected Panc-1 and Capan-1 cells yielded strong bands of the Bax and TRAIL transcripts 48 hours after infection, whereas the bands were extremely weak in siRNA hTERT-transfected cells and in fibroblasts infected with Ad-igBax or Ad-igTRAIL (Figure 2a) . In order to further confirm the transcriptional activity, Western blot experiments were carried out using specific Bax and TRAIL antibodies. As shown in Figure 2a , Bax and TRAIL protein expressions were readily achieved only in positive cells 48 hours after adenovirus infection. In contrast, there was little, if any, detectable Bax and TRAIL expressions in fibroblasts and in hTERT siRNA-transfected cells.
Ad-igBax and Ad-igTRAIL induce overexpression of Bax and TRAIL
In order to confirm the functionality and efficiency of the designed adenoviruses Ad-igBax and Ad-igTRAIL, the expressions induced by them were compared with those induced by the binary system using the PGK ubiquitous strong promoter (Ad/PGK-GV16 and Ad/GT-Bax). As shown in Figure 2b , RT-PCR and Western blot data showed that transduction of tumor cells by the adenoviruses bearing either strong promoter PGK or the tissue-specific promoter hTERT resulted in Bax and TRAIL-specific bands of equivalent intensity (in comparison with the constitutive gene glyceraldehyde 3-phosphate dehydrogenase), whereas mock infection resulted in low basal expression. These results provide evidence of the efficacy of the hTERT promoter used for generating Ad-igBax and Ad-igTRAIL.
In vitro assessment of the antitumor effect of Ad-igBax and Ad-igTRAIL
In order to evaluate the sensitivity of BxPC-3, Capan-1, and Panc-1 to the overexpressed Bax and TRAIL genes, cell cultures were infected with the inducible hTERT recombinant adenoviruses Ad-igBax and Ad-igTRAIL, alone (MOI of 50) or in combination (total MOIs of 100 and 200). As indicated in Figure 3a , cell transduction with either Bax or TRAIL adenovirus resulted in a significant decrease in cell viability. In the control cell cultures, Ad/CMV-GFP had no obvious effect on any of these cell lines. In contrast, there was a strong apoptopic effect on the tumor cell lines in response to Bax and TRAIL-expressing vectors. It is important to note that the cell death induced by Ad-igTRAIL was found to be more pronounced than that obtained with AdigBax, and their combination resulted in enhanced cytotoxicity. The Capan-1 and Panc-1 cell lines were more affected by the combined adenovirus infection. The combination of Ad-igBax and Ad-igTRAIL at a total MOI of 200 produced an apoptopic effect similar to that produced by an MOI of 100. These results demonstrate that a combination of adenoviruses mediating the overexpression of Bax and TRAIL significantly inhibits tumor cell growth. 
Enhanced efficacy of gemcitabine combined with Ad-igBax and Ad-igTRAIL
In order to determine whether a combination of Ad-igBax/ Ad-igTRAIL with gemcitabine can inhibit the resistance mechanisms leading to a synergistic antitumor effect, we devised an experiment to analyze the sensitivity of various pancreatic tumor cell lines. Our data showed that the concentrations of gemcitabine required for 50% growth inhibition (IC 50 ) were 5 × 10 8 mol/l, 10 -7 mol/l, and 10 -5 mol/l for BxPc3, Capan-1, and Panc-1, respectively (data not shown). We chose the concentration of 5 × 10 -8 mol/l for further experiments in order to best observe any benefit of combination therapy. Subsequently, the tumor cells were treated with gemcitabine (5 × 10 -8 mol/l) and Ad-igBax + Ad-igTRAIL (100 MOI), alone and in combination. As indicated in Figure 3b , our findings show clearly that the combined treatment resulted in a highly antiproliferative effect. More importantly, one can easily distinguish that the growth of the gemcitabine-resistant cell line Panc-1 was drastically inhibited. This Panc-1 tumor cell line was therefore selected for in vivo xenograft experiments.
Ad-igTRAIL plus Ad-igBax in combination with
Gemcitabine induced a high rate of apoptosis In order to confirm the results pertaining to cytotoxicity further, the Panc-1 tumor cell line was analyzed for apoptotic changes after treatment with Ad-igBax/Ad-igTRAIL and gemcitabine. After 3 days of treatment, Hoechst staining (Figure 4a and b) revealed a high chromatin condensation in the combined Bax/TRAIL-plus-gemcitabine treatment, and this was confirmed by the enzymatic terminal uridine deoxynucleotidyl transferase dUTP nick end labeling assay (Figure 4c and d) . The DNA fragmentation was more pronounced after combined treatment using Ad-igTRAIL plus Ad-igBax plus gemcitabine (Figure 4g) . We went on to examine whether the combined treatment would result in apoptosis of gemcitabine-resistant Panc-1 cells through activation of caspase-8, -9, and -3 (Figure 4h and i) . Data from enzyme-linked immunosorbent assay measurements showed that induction of caspase-3 and caspase-9 appeared to be primarily caused by Ad-igBax + AdigTRAIL activity, with minimal contribution from the addition of gemcitabine. Only the activation of caspase-8 was significantly enhanced by gemcitabine co-treatment with Ad-igBax + Ad-igTRAIL (P < 0.05).
The hTERT promoter prevents toxic side effects in vivo Finally, in order to assess liver toxicity in combined adenovirus or gemcitabine treatment, serum transaminase activity (glutamyl oxaloacetic transaminase, glutamyl pyruvic transaminase) was measured in mice after systemic and intratumoral administration of Ad-igBax or Ad-igTRAIL. Biological analysis showed that there was no significant elevation of serum transaminase levels in the animals. As regards glutamyl oxaloacetic transaminase and glutamyl pyruvic transaminase serum activity, no significant differences were seen between the groups receiving tumor therapy and an untreated control group. Gemcitabine, whether alone or in combination with adenoviruses, did not affect liver function ( Figure 5) . Additionally, the potential side effects in hematopoietic cells have been investigated, and the data clearly show that there were no significant changes in the values of hemoglobin, leukocytes, and platelets (data not shown). The statistical analysis showed that differences between combination-treated and control cells were statistically significant (***P < 0.001).
In vivo antitumor activity of Ad-igBax, Ad-igTRAIL, and gemcitabine
We next carried out a series of in vivo experiments to confirm the in vitro observations and to determine whether the efficacy of AdigBax/Ad-igTRAIL against pancreatic adenocarcinoma xenografts could be enhanced by using it in combination with gemcitabine. In order to evaluate adenovirus tumor transduction, we first investigated the levels of Bax gene expression at days 10 and 30 after treatment, using RT-PCR. In these experiments, we have compared our tetracycline-inducible Ad-igBax and Ad-igTRAIL with the binary system combining Ad/PGK-GV16 + Ad/GT-Bax, as described by Kagawa S. et al. 12 At day 10, Bax expression induced with Ad-igBax was significant and equivalent to that obtained with the non-specific PGK promoter. This expression was timedependant and appeared to persist for at least 3 weeks. Indeed, 30 days after infection, Bax messenger RNAs and proteins were reduced to the base level, whereas in Ad/igBax-infected tumors it was sustained (Figure 6a and b) .
In parallel, the tumor volumes were monitored for 7 weeks. As indicated in Figure 6c , tumors infected with Ad/CMV-GFP were not affected when compared with untreated tumors. However, gemcitabine reduced the tumor volume significantly (P < 0.01). More importantly, in the other treated groups, we observed that Ad-igBax or Ad-igTRAIL were able to reduce tumor growth significantly (P < 0.001), with the same efficacy as the adenovirus bearing a strong non-specific promoter does. The next experiments were focused on the antitumor efficacy of the combined treatment (inducible adenoviruses plus gemcitabine). As is shown in Figure 6d , the combination of Ad-igBax + Ad-igTRAIL with gemcitabine drastically reduced tumor growth. Together, these findings highlight the potential benefit of the combined therapeutic regimen using Bax/ TRAIL with gemcitabine in the treatment of pancreatic tumors.
In vivo tumor-specific targeting of Ad-igBax plus Ad-igTRAIL combined with gemcitabine
In order to obtain a clinical perspective, an experiment was carried out using mice bearing orthotopic pancreatic tumors "Panc-1/GFP". The animals were injected intraperitoneally three times ) are, respectively, the representative reverse transcriptase-polymerase chain reaction and immunoblot data obtained from tumor samples collected at day 10 and day 30 after treatment. For assessing tumor growth, the comparative antitumor effects of (c) single and (d) combined treatment modalities were evaluated as described in Materials and Methods. Statistical differences in tumor sizes were evaluated at the end of the experiment (NS, non significant, *P < 0.05, **P < 0.01, ***P < 0.001).
with Ad-igBax and Ad-igTRAIL. In order to evaluate gene targeting, Bax expression was investigated in liver, spleen, and tumor biopsies by RT-PCR and Western blot at days 10 and 30 after the last injection of adenoviruses. Figure 7a shows that the Bax gene is highly expressed in Ad-igBax-treated tumors. At the same time, it is worth noting that these mice showed a GFP expression restricted to the pancreatic tumor tissue, whereas in the control group this expression is present not only in the tumor, but also in the spleen and the liver. These results confirm the specific targeting and high expression of apoptotic gene driven by hTERT promoter. According to Kaplan-Meier, all the untreated control tumorbearing mice (Mock) and all those treated with Ad/CMV-GFP died within 43 and 48 days, respectively, as indicated in Figure 7b . Gemcitabine-treated mice died within 54 days (log Rank test, P < 0.05). However, 40% of the tumor-bearing mice treated with AdigBax plus Ad-igTRAIL were still alive after 2 months (log Rank test, P < 0.001), and a 60% survival rate was observed in the group receiving Ad-igBax/TRAIL plus gemcitabine (log Rank test, P < 0.001). At the autopsy, two-thirds of these surviving animals were tumor-free.
Real-time visualization of tumor growth and therapeutic efficacy evaluation As our tumor model stably expresses GFP fluorescence, it enables real-time, sequential whole body imaging without the need for laparotomy, use of contrast agent for computerized tomography scan, or invasive procedures. The monitoring of the tumor growth assessed by optical imaging showed progressive time-dependant fluorescence (Figure 8a) . The progression of disease in the control group (Ad/CMV-GFP) was rapid over the third and fourth weeks, leading ultimately to death in all the animals. On the contrary, after 1 month, the fluorescence in Bax/TRAIL-treated mice was significantly less than in AdCMV/GFP-treated mice. The fluorescence signal became minimally detectable when animals were cotreated with Ad-igBax/Ad-igTRAIL and gemcitabine. As shown in Figure 8b , tumor-bearing mice treated with Ad/CMV-GFP showed an increase of abdominal girth indicative of ascites and therefore tumor burden. These data were confirmed by autopsy examination. A very large tumor with locoregional invasion of vital structures was present in an Ad/GFP-treated mouse as compared to the very small tumor in a mouse receiving combined treatment.
DISCUSSION
Gemcitabine-based chemotherapy is considered the standard of care for most patients with locally advanced pancreatic cancer. [20] [21] [22] However, clinical reports have indicated the development of chemoresistance in gemcitabine-treated patients. 23 Strategies for overcoming resistance are essential to the success of anticancer therapy. Several studies have reported that resistance to apoptosis controls the ability of tumors to withstand high levels of chemotherapy. 24 Therefore, the development of approaches to enhance the apoptotic threshold within tumor cells is likely to prove useful both as a direct cancer treatment and in combination with chemotherapy. TRAIL and Bax are two The survival rate of orthotopic tumor-bearing mice was monitored over time after treatment, and plotted as a Kaplan-Meier plot. The significance level versus mock was P < 0.05 for gemcitabine, P < 0.01 for Ad-igBax/Ad-igTRAIL, and P < 0.001 for Ad-igBax/Ad-igTRAIL plus gemcitabine. The differences between AdigBax/Ad-igTRAIL plus gemcitabine and Ad-igBax/Ad-igTRAIL treated groups were compared and considered significant (P < 0.05). of the well-characterized proapoptotic genes, and their overexpression leads to apoptosis in a wide variety of malignant cells, with or without additional stimuli. 25, 26 For a long time, apoptotic genes were speculated to be toxic for normal tissues. One common approach to target transgene expression is to use tissue-or cell-specific promoters, 27 one of which is the catalytic subunit of telomerase, hTERT. Indeed, it has been reported that telomerase activity is significantly higher in approximately 90% of cancers, and correlates well with the degree of malignancy. We therefore designed inducible tetracycline-recombinant adenoviruses, using the hTERT promoter sequence to target Bax and TRAIL gene expression. Additionally, we deliberately opted to use the Tet-Off system for two reasons (i) to directly control the production and amplification of the proapoptotic adenoviruses, and (ii) so that the tetracycline product could serve as an antidote in the case of any apparent cytotoxicity in vivo. In order to track the recombinant vector (and, indirectly, the proapoptotic gene in vivo) we constructed a bicistronic vector including a GFP with IRES.
In order to assess the antitumor activity, Ad-igBax and AdigTRAIL were used alone or in combination with gemcitabine. Our data showed that gemcitabine sensitized pancreatic cancer cells to Bax/TRAIL-mediated apoptosis. The sensitization can be obtained at subtoxic concentrations of gemcitabine and for a short duration of treatment. The combined treatment (AdigBax/Ad-igTRAIL with gemcitabine) drastically reduced tumor growth in the subcutaneous tumor model. Even if this result is not statistically significant, there is an unmistakable indication of reduction in tumor volume after combination therapy. We think that higher doses of the recombinant adenoviruses should be used for producing a more pronounced antitumor effect. In an experiment applicable to a clinic setting, we used an orthotopic pancreatic cancer model to demonstrate that combining Ad-igBax/Ad-igTRAIL with gemcitabine not only prolonged survival (almost two-thirds of the animals were still alive after 2 months), but also rendered 40% of the mice tumor-free at autopsy. The broad range of MOIs used for infecting cells and delivering transgenes in various gene therapy studies reflects both the lack of consensus among investigators for standardization of adenovirus vector concentrations and the fact that MOIs, especially in ex vivo and in vivo experiments, are estimated values based on arbitrary assumptions. In the present work, based on the commonly used convention of assuming approximately 10 8 cells per 1 cm 3 tumor, the significant in vivo antitumor efficacy and improved survival following the relatively low doses of Ad-igBax and Ad-igTRAIL (2 × 10 9 viral particles per dose) support the use of this safe and efficient apoptogene therapy protocol combined with gemcitabine. Furthermore, there was no detectable hepatotoxicity, and normal tissues from various organs were not affected by these treatments. In contrast, Ad/ CMV-GFP generated expression in tumor but also in normal tissues such as liver and spleen of control mice. When mice were treated with Ad-igBax, significant GFP and Bax expressions were limited solely to the pancreatic tumor. This shows that hTERT promoter restricts the proapoptotic gene expression to tumor cell tissue, as corroborated by the apparent absence of liver toxicity. These findings show a synergistic tumor cytotoxic activity of Bax and TRAIL in combination with gemcitabine, thereby supporting the use of this approach in drug-resistant pancreatic cancer therapy.
Fluorescence molecular imaging systems allow follow-up of tumor development and growth in live animals. [28] [29] [30] [31] Molecular imaging protocols can achieve these goals in real-time, noninvasively, rapidly, quantitatively, and repetitively in the same animal, under different conditions and stimuli. Moreover, this optical imaging strategy can improve the accuracy and efficiency of therapeutic schedules and avoid treatment remission. In the present study, the assessment of the antitumor activity was evaluated by caliper measurements of subcutaneous tumor model. This method is the most popular technique for cancer drug evaluation. However, it is not convenient for the increasingly used orthotopic or transgenic systems. Non-invasive imaging is ideally suited for follow-up studies on tumor growth and gene expression. Our results obtained with the orthotopic pancreatic cancer model confirm the antitumor effect of the combined treatment protocol (AdigBax/Ad-igTRAIL + gemcitabine). Up to day 7, no fluorescence signal was detectable in any of the mice that were examined. From day 10, molecular imaging could distinguish the control group from the others by a direct visualization of the tumors, which were almost invisible in the treated groups. These results were clearly in accordance with the laparatomy examination and with survival curve determination.
In this regard, establishing the correct therapeutic "window" of application for each tumor growth inhibitor (such as gene therapy intervention), or for drug combination, will be crucial in the management of pancreatic cancer treatment. The proof of this concept was elegantly demonstrated using optical imaging technology to follow up the efficacy of apoptogene therapy in combination with chemotherapy in an orthotopic pancreatic cancer model.
To summarize: on the one hand we provide solid evidence that apoptogene therapy targeting Bax and TRAIL combined with an optimized gemcitabine protocol constitutes a promising new approach to pancreatic cancer treatment and, on the other hand, we corroborate the usefulness of molecular imaging, which facilitates and accelerates the evaluation of the therapeutic efficacy of new anticancer strategies. As most of the patients will continue to present with unresectable pancreatic cancer, it is clear that the most effective therapy will require a combined approach incorporating the best-targeted interventions. Presently, we have combined conventional and new therapeutic approaches. The results suggest that multimodality therapy regimens using targeted suicide-apoptogene therapy that can overcome chemoresistance will provide new promise for pancreatic cancer treatment in the future.
Taking into account the data from this study and others, we believe that the concept of treating all patients with the same protocols will be given up by oncologists in the near future, and we are convinced that multimodal therapy is needed. It is crucial that we move forward with scientifically driven innovative therapies, as the empirical approaches have failed.
